* VBI Vaccines Inc VBIV.OQ VBIV.O is expected to show a
rise
in quarterly revenue when it reports results on August 7
(estimated).
* The Cambridge Massachusetts-based company is expected to
report
a 168.5% increase in revenue to $929 thousand from $346
thousand a year ago, according to the estimate from one analyst,
based on Refinitiv data.
* Refinitiv's mean analyst estimate for VBI Vaccines Inc is
for a
loss of $2.16 per share.
* The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 2 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for VBI
Vaccines Inc
is $4, above its last closing price of $1.27.
This summary was machine generated August 4 at 18:39 GMT. All
figures in US dollars unless otherwise stated